UBS AM
LYEL icon

UBS AM’s Lyell Immunopharma LYEL Stock Holding History

UBS AM’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,795
Closed -$270K – 2721
2024
Q3 		$270K Buy
9,795
+165
+2% +$4.85K ﹤0.01% 2742
2024
Q2 		$279K Buy
9,630
+7,980
+484% +$380K ﹤0.01% 2730
2024
Q1 		$73.6K Hold
1,650
– – ﹤0.01% 2500
2023
Q4 		$64K Hold
1,650
– – ﹤0.01% 2535
2023
Q3 		$48.5K Buy
+1,650
New +$78.4K ﹤0.01% 2581

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

UBS AM's LYEL Position: Q4 2024 in Review

UBS AM sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 9,795 shares — an estimated $270K sold.

UBS AM first reported a position in LYEL in Q3 2023 and held it in 5 quarters. The position peaked at $279K in Q2 2024. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • UBS AM reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • UBS AM sold 9,795 Lyell Immunopharma shares in Q4 2024, an estimated $270K.
  • UBS AM first reported a position in Lyell Immunopharma in Q3 2023 and held it in 5 quarters.
  • UBS AM's Lyell Immunopharma position peaked at $279K in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on UBS AM's 13F filing for Q4 2024, filed 14 Feb 2025.